Anti-corruption, Compliance Scrutiny Increases In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Anti-corruptions officials - whose interests are not scientific but regulatory - have started paying increasing attention to the life sciences sector in recent years
You may also be interested in...
SciClone's Quarter Sales Growth Marred By FCPA Investigation Of China Operations
HONG KONG - U.S. regulatory authorities have launched an investigation into the China operations of Hong Kong-based and Nasdaq-listed SciClone Pharmaceuticals, a specialty pharmaceutical company
SciClone's Quarter Sales Growth Marred By FCPA Investigation Of China Operations
HONG KONG - U.S. regulatory authorities have launched an investigation into the China operations of Hong Kong-based and Nasdaq-listed SciClone Pharmaceuticals, a specialty pharmaceutical company
China Arrests Five SFDA Officials On Bribery Charges
SHANGHAI - Chinese authorities earlier this month arrested five officials from the State FDA and the National Institute for the Control of Pharmaceutical and Biological Products for taking bribes, according to reports by the government-run Xinhua News Agency